Schema Version: 2.0
Call Record ID: V6300000000R002
Vault ID: 258734
Call Object Type: Call Report
Account ID: V4T000000007457
Account: Clinton Ackerman
Owner: Sarah Jones
Territory: USONC-1100
Date: 2026-10-05
Datetime: 2026-10-05T20:13
Channel: In-person
Call Type: Detail with Sample
Duration: 30 min
Status: Saved
Is Sampled Call: No
Group Call: Parent
Unique Activities: No
Attendees: 3
Products Detailed: 1
Key Messages: 2
Samples Dropped: 1
Expenses: 0
---

## Attendees
| Attendee | ID | Type | Child call ID |
|---|---|---|---|
| Blankenship, Domenic | V4T000000007459 | Professional | V6300000000R004 |
| Denny, Tyrique | V4T000000007458 | Professional | V6300000000R006 |

## Products Detailed
| Priority | Product | Type |
|---|---|---|
| 1 | Natevba | Paper_Detail |

## Key Messages
| Product | Key Message | Category | Reaction |
|---|---|---|---|
| Natevba | Primary Endpoint Results | | Positive |
| Natevba | Hospital Treatment Outcomes | Efficacy | Negative |

## Samples Dropped
| Product | Qty |
|---|---|
| Natevba $25 Co-Pay Packet | 1 |

## Related Activity
**Commercial Insights:** There is a significant safety over efficacy threshold for oncologists. (Natevba; Source: Call) — Saved, 2026-10-05
**Call Objectives:** CO-00000005

## Call Notes
- Practice has seen positive outcomes this quarter, good sentiment for switching.
- Told her payors are approving Natevba for C81. Can we add the diagnosis code to the Natevba quick reference guide? Nurses like using it.
- Provided updated PI and reviewed the recommended dosing schedule.
- Q's about administration protocols and infusion times.
- Discussed speaker program, she will register.
- Dropped new brochures and patient support program cards at FD.